Most Read Articles
Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
27 Sep 2019
Quadrivalent influenza vaccine (split virion, inactivated) 0.5 mL inj
Jairia Dela Cruz, 23 Sep 2020
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.
Stephen Padilla, 17 Dec 2019
The use of aspirin for primary prevention in patients without known cardiovascular diseases (CVDs) significantly reduces the risk of myocardial infarction (MI) but increases that of major bleeding and haemorrhagic stroke, according to a meta-analysis.

Pregabalin as monotherapy enough to manage fibromyalgia

26 Sep 2020

Pregabalin, used either alone or in combination with milnacipran, is effective in the treatment of patients with fibromyalgia, and combined therapy does not confer added benefits compared with monotherapy, according to a study.

The study randomized 58 female fibromyalgia patients to receive pregabalin 150 mg twice daily alone (n=29) or with milnacipran 50 mg twice daily (n=29) for 3 months. The median disease duration was 2 years, with an average tender point count of 14.

Patients in the combination arm had a numerically higher visual analogue scale (VAS) and fibromyalgia impact questionnaire (FIQ) scores, with 22 (84.6 percent) of them having severe pain (VAS ≥70) as compared with 15 (65.2 percent) in the monotherapy group. Pain was significantly correlated with disease impact at baseline in both groups.

The dropout rate was 20.7 with monotherapy and 10.3 percent with combination. At the follow‐up assessment, patients in both groups showed a statistically significant improvement in VAS and FIQ scores (p<0.001).

More patients on combination than on monotherapy achieved significant improvement in pain, disease impact, and sleep pattern. However, the difference was not clinically meaningful.

In light of the results, the researchers acknowledged that a population-based, multicentric study may reveal more significant findings. They suggested that future studies consider adding a placebo control and milnacipran comparator groups with blinding to obtain better data.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
27 Sep 2019
Quadrivalent influenza vaccine (split virion, inactivated) 0.5 mL inj
Jairia Dela Cruz, 23 Sep 2020
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.
Stephen Padilla, 17 Dec 2019
The use of aspirin for primary prevention in patients without known cardiovascular diseases (CVDs) significantly reduces the risk of myocardial infarction (MI) but increases that of major bleeding and haemorrhagic stroke, according to a meta-analysis.